Patienter med ALL, som ikke har responderet på, eller som har haft tilbagefald efter at have modtaget mindst to behandlinger, har en meget lille chance for at overleve.
Patients with ALL who have not responded to or who have relapsed after receiving at least two treatments have a very poor chance of survival.